HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SLC9A6
solute carrier family 9 member A6
Chromosome X Β· Xq26.3
NCBI Gene: 10479Ensembl: ENSG00000198689.13HGNC: HGNC:11079UniProt: A0A0D9SGH0
57PubMed Papers
22Diseases
0Drugs
65Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedTransporter
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
mitochondrionregulation of intracellular pHplasma membranedendrite extensionChristianson syndromeIntellectual disabilitygenetic disordermicrocephaly
✦AI Summary

SLC9A6 encodes an endosomal Na+, K+/H+ antiporter that mediates electroneutral exchange of endosomal luminal H+ for cytosolic Na+ or K+ 1234. By facilitating proton efflux, SLC9A6 counteracts vacuolar ATPase-generated acidity, thereby maintaining endosomal pH and enabling endosome maturation and recycling endosomal cargo trafficking 1234. The transporter plays critical roles in neurodevelopment, regulating synaptic development and plasticity, and maintains cell polarity through intravesicular pH modulation 5. Mutations in SLC9A6 cause ChrX syndrome, an X-linked intellectual developmental disorder characterized by global developmental delay, epilepsy, hyperkinesis, ataxia, and microcephaly 6. Frameshift variants result in loss of functional NHE6 protein, with emerging evidence suggesting mitochondrial dysfunction and lipid metabolism alterations contribute to pathogenesis 6. Female carriers exhibit variable phenotypes including learning difficulties, mild-to-moderate intellectual disability, behavioral issues, and psychiatric illness 7. SLC9A6 is increasingly recognized among X-linked epilepsy genes associated with developmental and epileptic encephalopathies 8. Gene-specific variant interpretation criteria have been established to improve diagnostic accuracy 9.

Sources cited
1
SLC9A6 is an endosomal Na+, K+/H+ antiporter mediating proton efflux and maintaining endosomal pH
PMID: 15522866
2
SLC9A6 facilitates endosome maturation and recycling endosomal cargo trafficking
PMID: 28635961
3
SLC9A6 functions as endosomal Na+, K+/H+ antiporter regulating luminal acidification
PMID: 31676550
4
SLC9A6 mediates electroneutral H+/Na+ or K+ exchange in endosomes
PMID: 32277048
5
SLC9A6 maintains cell polarity through modulation of intravesicular pH
PMID: 20130086
6
SLC9A6 frameshift mutations in Christianson syndrome cause loss of NHE6 protein and mitochondrial/lipid metabolism dysfunction
PMID: 37381736
7
Female SLC9A6 mutation carriers exhibit learning difficulties, intellectual disability, behavioral and psychiatric issues
PMID: 27142213
8
SLC9A6 mutations cause X-linked epilepsy and developmental and epileptic encephalopathies
PMID: 38612920
9
Gene-specific variant interpretation criteria have been established for SLC9A6 by the Rett/AS VCEP
PMID: 34837432
Disease Associationsβ“˜22
Christianson syndromeOpen Targets
0.83Strong
Intellectual disabilityOpen Targets
0.54Moderate
genetic disorderOpen Targets
0.45Moderate
microcephalyOpen Targets
0.40Moderate
Angelman syndromeOpen Targets
0.37Weak
neurodegenerative diseaseOpen Targets
0.37Weak
SeizureOpen Targets
0.29Weak
Global developmental delayOpen Targets
0.26Weak
Gastrostomy tube feeding in infancyOpen Targets
0.26Weak
Recurrent respiratory infectionsOpen Targets
0.26Weak
scoliosisOpen Targets
0.26Weak
Sleep disturbanceOpen Targets
0.26Weak
Neurodevelopmental disorderOpen Targets
0.12Weak
AllergyOpen Targets
0.12Weak
amblyopiaOpen Targets
0.12Weak
EEG with generalized slow activityOpen Targets
0.12Weak
HypermetropiaOpen Targets
0.12Weak
leukodystrophyOpen Targets
0.12Weak
Motor delayOpen Targets
0.12Weak
Short statureOpen Targets
0.12Weak
Intellectual developmental disorder, X-linked, syndromic, Christianson typeUniProt
Neurodegenerative disorder, X-linked, female-restricted, with parkinsonism and cognitive impairementUniProt
Pathogenic Variants65
NM_001379110.1(SLC9A6):c.370-9_370-5delPathogenic
not specified|Intellectual disability|Christianson syndrome|Inborn genetic diseases
β˜…β˜…β˜…β˜†2022
NM_001379110.1(SLC9A6):c.448-1G>APathogenic
not provided|Christianson syndrome|Thyroid cancer, nonmedullary, 1|Nonpapillary renal cell carcinoma
β˜…β˜…β˜…β˜†2021
NM_001379110.1(SLC9A6):c.916C>T (p.Gln306Ter)Pathogenic
not provided|Christianson syndrome
β˜…β˜…β˜…β˜†2021β†’ Residue 306
NM_001379110.1(SLC9A6):c.460C>T (p.Arg154Ter)Pathogenic
Christianson syndrome|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 154
NM_001379110.1(SLC9A6):c.743+3_743+6delPathogenic
not provided|Christianson syndrome
β˜…β˜…β˜†β˜†2025
NM_001379110.1(SLC9A6):c.1342C>T (p.Arg448Ter)Pathogenic
Christianson syndrome|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 448
NM_001379110.1(SLC9A6):c.743+1G>APathogenic
not provided|Christianson syndrome|Thyroid cancer, nonmedullary, 1
β˜…β˜…β˜†β˜†2023
NM_001379110.1(SLC9A6):c.1661+1G>APathogenic
not provided
β˜…β˜…β˜†β˜†2022
NM_001379110.1(SLC9A6):c.1438dup (p.Met480fs)Pathogenic
not provided|Christianson syndrome
β˜…β˜…β˜†β˜†2022β†’ Residue 480
NM_001379110.1(SLC9A6):c.1143_1144del (p.Phe382fs)Pathogenic
not provided|6 conditions|Christianson syndrome
β˜…β˜…β˜†β˜†2015β†’ Residue 382
NM_001379110.1(SLC9A6):c.28C>T (p.Gln10Ter)Likely pathogenic
Christianson syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 10
NM_001379110.1(SLC9A6):c.1142del (p.Leu381fs)Pathogenic
Christianson syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 381
NM_001379110.1(SLC9A6):c.1024C>T (p.Gln342Ter)Pathogenic
Christianson syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 342
NM_001379110.1(SLC9A6):c.169+4402_370-1100dupLikely pathogenic
Christianson syndrome
β˜…β˜†β˜†β˜†2025
NM_001379110.1(SLC9A6):c.170G>A (p.Gly57Asp)Likely pathogenic
Christianson syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 57
NM_001379110.1(SLC9A6):c.1418_1419del (p.Phe473fs)Pathogenic
Christianson syndrome
β˜…β˜†β˜†β˜†2024β†’ Residue 473
NM_001379110.1(SLC9A6):c.459dup (p.Arg154fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 154
NM_001379110.1(SLC9A6):c.1625_1643del (p.Ala542fs)Likely pathogenic
Christianson syndrome
β˜…β˜†β˜†β˜†2024β†’ Residue 542
NM_001379110.1(SLC9A6):c.1186G>T (p.Gly396Ter)Pathogenic
Christianson syndrome
β˜…β˜†β˜†β˜†2024β†’ Residue 396
NM_001379110.1(SLC9A6):c.886-1C>TLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2024
View on ClinVar β†—
Related Genes
SLC9B2Protein interaction92%SLC9A7Protein interaction83%DIPK2AProtein interaction82%RACK1Protein interaction73%NPAS4Protein interaction70%SLC9A4Shared pathway64%
Tissue Expression6 tissues
Brain
100%
Heart
31%
Bone Marrow
25%
Ovary
14%
Lung
12%
Liver
9%
Gene Interaction Network
Click a node to explore
SLC9A6SLC9B2SLC9A7DIPK2ARACK1NPAS4SLC9A4
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q92581
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.26Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.13 [0.07–0.26]
RankingsWhere SLC9A6 stands among ~20K protein-coding genes
  • #8,016of 20,598
    Most Researched57
  • #1,109of 5,498
    Most Pathogenic Variants65 Β· top quartile
  • #851of 17,882
    Most Constrained (LOEUF)0.26 Β· top 5%
Genes detectedSLC9A6
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
X-Linked Epilepsies: A Narrative Review.
PMID: 38612920
Int J Mol Sci Β· 2024
1.00
2
Recommendations by the ClinGen Rett/Angelman-like expert panel for gene-specific variant interpretation methods.
PMID: 34837432
Hum Mutat Β· 2022
0.90
3
A novel peptide encoded by circ-SLC9A6 promotes lipid dyshomeostasis through the regulation of H4K16ac-mediated CD36 transcription in NAFLD.
PMID: 39107881
Clin Transl Med Β· 2024
0.80
4
Structural and functional implications of SLC13A3 and SLC9A6 mutations: an in silico approach to understanding intellectual disability.
PMID: 37794328
BMC Neurol Β· 2023
0.70
5
SLC gene mutations and pediatric neurological disorders: diverse clinical phenotypes in a Saudi Arabian population.
PMID: 34797406
Hum Genet Β· 2022
0.60